STENTiT is a medical device company and spin-off from Eindhoven University of Technology led by CEO Bart Sanders. It develops a novel class of regenerative endovascular implants—regenerative stents—designed to restore arteries from the inside out using catheter-based approaches, avoiding invasive surgery. The company aims to provide lifelong solutions for cardiovascular diseases, including peripheral indications. STENTiT intends to use the funds from its recent seed round to facilitate further pre-clinical development and batch production of its regenerative stent for peripheral indications. The product development is at the pre-clinical stage per the article. The company is headquartered in Eindhoven, The Netherlands.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2022